At the 2024 American Academy of Neurology Annual Meeting, NeurologyLive® sat down with Parkinson disease (PD) expert Daniel Kremens, MD, JD, to discuss some of the top data being ...

Helen Colquhoun, MD(Credit: LinkedIn)Recently published in Movement Disorders, results from the double-blind, randomized, placebo-controlled, phase 2 KINETIC trial (NCT04305275) as...

At the 2024 American Academy of Neurology Annual Meeting, NeurologyLive® sat down with Parkinson disease (PD) expert Daniel Kremens, MD, JD, to discuss some of the top data being ...

Claire Henchcliffe, MD(Credit: Weill Cornell Medicine)According to a recent report from GlobalData, using data from BlueRock Therapeutics’ phase 1 study (NTC04802733) assessing be...

Jacqueline A. French, MDCredit: NYU LangoneAccording to a recently published study in Neurology, findings showed that nonmotor seizures go undetected two-thirds of the time in pedi...

WATCH TIME: 3 minutes'For many years, those of us who specialize in these disorders have seen patients with very similar features that the patients with Long COVID have. Many of th...

Newly announced preliminary top-line results from a planned interim analysis of a phase 2 study (NCT04845178) showed that treatment with ABP-450 (AEON Biopharma) did not meet its p...

This is a video synopsis/summary of a panel discussion involving Michael Thorpy, MD; Karl Doghramji, MD, FAASM, DFAPA; Clete Kushida, MD, PhD; and Richard K Bogan, MD.Experts discu...

This is a video synopsis/summary of a panel discussion involving Michael Thorpy, MD; Karl Doghramji, MD, FAASM, DFAPA; Clete Kushida, MD, PhD; and Richard K Bogan, MD.The discussio...

WATCH TIME: 6 minutes'It's important because when patients finally seek treatment for agitation and aggression that’s been going on for quite a while and has gotten to a critical ...